Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken: * before starting treatment with pembrolizumab. * undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients of both sexes aged ≥ 18 years at enrollment
• Patients affected by cHL R/R candidate to receive a treatment with Pembrolizumab
• Signature of informed consent
Locations
Other Locations
Italy
IRCCS Azienda Ospedaliero - Universitaria di Bologna
RECRUITING
Bologna
Contact Information
Primary
Pier Luigi Zinzani, MD
pierluigi.zinzani@unibo.it
+390512144042
Backup
Beatrice Casadei, MD
beatrice.casadei@aosp.bo.it
+390512144042
Time Frame
Start Date: 2024-08-01
Estimated Completion Date: 2027-02-01
Participants
Target number of participants: 40
Related Therapeutic Areas
Sponsors
Leads: IRCCS Azienda Ospedaliero-Universitaria di Bologna